Zoledronic acid, sold in the U.S. by Novartis under the brand name Reclast, just received final approval from the FDA for the treatment of osteoporosis.
The bisphosphonate medication is taken intravenously once a year and has been on the market to treat other bone diseases.
Its approval for osteoporosis adds a major new option for those unable to tolerate oral bisphophonate regimens.
Check back this week for additional SharePosts on the process of taking Reclast (Zoledronic acid), the potential side effects of the drug, and the long-term outcomes for bone health .
Published On: August 19, 2007